KR860001185A - Csf의 취득방법 - Google Patents

Csf의 취득방법 Download PDF

Info

Publication number
KR860001185A
KR860001185A KR1019850005125A KR850005125A KR860001185A KR 860001185 A KR860001185 A KR 860001185A KR 1019850005125 A KR1019850005125 A KR 1019850005125A KR 850005125 A KR850005125 A KR 850005125A KR 860001185 A KR860001185 A KR 860001185A
Authority
KR
South Korea
Prior art keywords
fraction
csa
neutrophil
csf
iii
Prior art date
Application number
KR1019850005125A
Other languages
English (en)
Other versions
KR920009496B1 (ko
Inventor
마사요시 오노 (외 1)
Original Assignee
우에노 기미오
쥬우가이 세이야꾸 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15558855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR860001185(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 우에노 기미오, 쥬우가이 세이야꾸 가부시끼 가이샤 filed Critical 우에노 기미오
Publication of KR860001185A publication Critical patent/KR860001185A/ko
Application granted granted Critical
Publication of KR920009496B1 publication Critical patent/KR920009496B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/145—Colony stimulating factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

CSF의 취득방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명의 CSF의 SDS-PAGE의 결과를 나타낸다. 도면중 .가 본 발명의 CSF이다.
제2도는 4M 요소 존재하에 있어의 본 발명의 CSF의 등전 점전기 영동의 결과를 나타낸다.
제3도는 본 발명의 CSF의 UV 흡수 스펙트럼이다.
제4도는 CHU-1의 증식능을 나타낸다.
제5도는 제1도와 같이 본 발명의 CSF의 SDS-PAGE의 결과를 나타낸다. 도면중 .가 본 발명의 CSF이다.

Claims (2)

  1. 사람 G-CSF 생산능을 갖는 세포주를 혈청 무첨가 배양액으로 배양하고, 그 배양상청을 ① 5,000∼70,000달톤 실행분획범위를 갖는 겔을 사용한 겔여과 시키고, 호중구 우위의 콜로니 형성촉진 활성(이하「CSA」라 한다)을 갖는 획분을 회수하고, ② ①의 획분을 역상계 고속액체 크로마토그래피 담체에 흡착시키고, 물과 유기용매의 혼액의 농도구배에 의하여 용출하고, 호중구 우위의 CSA을 갖는 획분을 회수하고 ③ ②의 획분을 고속분자체 크로마토그래피하고, 호중구 우위의 CSA를 갖는 획분을 회수한후, 필요에 따라서, ④ ③의 획분을 등전점기영동하고, 호중구 우위의 CSA를 갖는 획분을 회수 하거나, ⑤ ③의 획분에 시알산제거 조작을 실시한 후, 호중구 우위의 CSA를 갖는 획분을 회수함을 특징으로 하는, 다음의 이화학적 성질을 갖는 CSF의 취득방법
    「이화학적 성질」
    (ⅰ) 분자량 : 도데실 황산나트륨-폴리아크릴아미드겔 전기 영동법에 의한 측정에 의하여 19,000±1,000.
    (ⅱ) 동전점 : 다음의 표-1에 나타내는 3개의 등전점(A,B,C)중, 적어도 하나를 갖는다.
    [표-1]
    (ⅲ) 자외선흡수 : 280nm에서 극대흡수를 갖고, 250nm에서 극소치를 갖는다.
    (ⅳ) N말단으로부터 21잔기째까지의 아미노산 배열이 다음과 같다.
  2. 제1항에 있어서, 사람 G-CSF 생산능을 갖는 세포주가 CHU-1인 CSF의 취득방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019850005125A 1984-07-25 1985-07-18 Csf의 취득방법 KR920009496B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP59153273A JPS61227526A (ja) 1984-07-25 1984-07-25 新規なコロニー刺激因子
JP153273 1984-07-25
JP59-153273 1984-07-25

Publications (2)

Publication Number Publication Date
KR860001185A true KR860001185A (ko) 1986-02-24
KR920009496B1 KR920009496B1 (ko) 1992-10-17

Family

ID=15558855

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019850005125A KR920009496B1 (ko) 1984-07-25 1985-07-18 Csf의 취득방법

Country Status (17)

Country Link
US (1) US4833127A (ko)
EP (1) EP0169566B2 (ko)
JP (1) JPS61227526A (ko)
KR (1) KR920009496B1 (ko)
AR (1) AR242835A1 (ko)
AT (1) ATE35271T1 (ko)
BG (1) BG61494B2 (ko)
CA (1) CA1312569C (ko)
DE (1) DE3563444D1 (ko)
DK (1) DK166731B1 (ko)
ES (1) ES8609365A1 (ko)
FI (1) FI83881C (ko)
HK (1) HK50491A (ko)
NL (1) NL930141I2 (ko)
NO (1) NO168952C (ko)
SG (1) SG41591G (ko)
ZA (1) ZA855478B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210007520A (ko) * 2019-07-12 2021-01-20 차원방 호안보강 및 확장을 위한 호안의 확장매립 시공방법

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
US6117422A (en) * 1985-02-05 2000-09-12 Chiron Corporation N∇2-CSF-1(long form) and carboxy truncated fragments thereof
US5573930A (en) * 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US6156300A (en) * 1985-02-05 2000-12-05 Chiron Corporation Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5792450A (en) * 1985-02-05 1998-08-11 Chiron Corporation Purified human CSF-1
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
AU594045B2 (en) * 1985-02-05 1990-03-01 Chiron Corporation Recombinant colony stimulating factor-1
WO1986004605A1 (en) * 1985-02-08 1986-08-14 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor
US5532341A (en) * 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
ATE67517T1 (de) * 1985-09-30 1991-10-15 Chugai Pharmaceutical Co Ltd Menschlicher granulozyten-colony stimulierender faktor.
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
EP0231819B1 (en) * 1986-01-22 1992-04-01 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical agent for the treatment of myelogenous leukemia
ES2039209T5 (es) * 1986-01-22 1996-07-16 Chugai Pharmaceutical Co Ltd Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica.
US5160490A (en) * 1986-04-18 1992-11-03 Marrow-Tech Incorporated Three-dimensional cell and tissue culture apparatus
US4963489A (en) * 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5266480A (en) * 1986-04-18 1993-11-30 Advanced Tissue Sciences, Inc. Three-dimensional skin culture system
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5510254A (en) * 1986-04-18 1996-04-23 Advanced Tissue Sciences, Inc. Three dimensional cell and tissue culture system
ZA872705B (en) * 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
JP2583770B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
JPH0725689B2 (ja) * 1986-10-07 1995-03-22 中外製薬株式会社 顆粒球コロニ−刺激因子を含有する徐放性製剤
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
US5214132A (en) * 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
DK174044B1 (da) * 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
US5194592A (en) * 1986-12-23 1993-03-16 Kyowa Hakko Kogyo Co. Ltd. Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5202117A (en) * 1988-08-24 1993-04-13 Koichiro Tsuji Method of treating thrombi with g-csf
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US6166183A (en) * 1992-11-30 2000-12-26 Kirin-Amgen, Inc. Chemically-modified G-CSF
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
JPH0322973A (ja) * 1989-01-19 1991-01-31 Wan Shen-Yuan ヒトヘパトーム細胞系によるコロニー形成促進因子（ＣＳＦｓ）の構成性産生
KR920701252A (ko) * 1989-10-10 1992-08-11 스티븐 엠. 오드레 과립구 군체 자극인자 및 그를 이용하여 개 및 고양이과 동물의 전염병을 치료하거나 예방하는 방법
US5147799A (en) * 1990-04-25 1992-09-15 Isia Bursuker Repopulation of macrophages and granulocytes using transforming growth factor-beta
GB2253852B (en) * 1991-02-26 1995-03-22 Ici Plc Vector for expression of heterologous polypeptide comprising inducible selection system
NZ241954A (en) * 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US7208473B2 (en) * 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
US6627186B1 (en) 1999-01-06 2003-09-30 Xencor Nucleic acids and protein variants of hG-CSF with granulopoietic activity
ATE246202T1 (de) * 1999-01-29 2003-08-15 Hoffmann La Roche Gcsf konjugate
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
FR2820979B1 (fr) 2001-02-22 2004-03-12 Didier Pourquier Nouvelle application therapeutique du g-csf
MXPA04000231A (es) * 2001-07-11 2004-05-04 Maxygen Holdings Ltd Conjugados del factor de estimulacion de colonias de granulocitos.
SI21102A (sl) 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
PT1463751E (pt) 2001-12-21 2013-08-26 Human Genome Sciences Inc Proteínas de fusão de albumina
AU2003261723A1 (en) 2002-08-27 2004-03-19 Takeda Chemical Industries, Ltd. Cxcr4 antagonist and use thereof
CA2607844C (en) 2005-06-01 2012-07-10 Maxygen Holdings Ltd. Pegylated g-csf polypeptides and methods of producing same
EP2094274A4 (en) 2006-12-21 2011-05-11 Biokine Therapeutics Ltd T-140 PEPTIDE ANALOGUE WITH CXCR4 SUPERAGONIST ACTIVITY FOR BONE MARROW RECOVERY
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
US20120114594A1 (en) 2009-05-14 2012-05-10 Keiichi Fukuda Muscle repair promoter
CN102481332A (zh) 2009-06-14 2012-05-30 拜欧肯疗法有限公司 用于提高血小板水平的肽疗法
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
WO2017009842A2 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
ES2830726T3 (es) 2016-02-23 2021-06-04 Biolinerx Ltd Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4135975A (en) * 1977-12-14 1979-01-23 Lichtman Marshall A Obtaining human cell lines that elaborate colony stimulating activity for marrow cells of man and other species and methods of preparing same
JPS54140789A (en) * 1978-04-22 1979-11-01 Jitsuken Doubutsu Chuo Kenkiyu Culturing of colony stimulating factor producing tumor cell
US4230697A (en) * 1978-07-03 1980-10-28 Morinaga Milk Industry Co. Ltd. Virus-inactivated HGI-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same
US4342828A (en) * 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
JPS6030654B2 (ja) * 1980-12-31 1985-07-17 株式会社林原生物化学研究所 ヒトコロニ−刺激因子の製造方法
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
JPS5978122A (ja) * 1982-10-27 1984-05-04 Ajinomoto Co Inc コロニ−刺激因子の製造法
JPS59169489A (ja) * 1983-03-15 1984-09-25 Otsuka Pharmaceut Co Ltd ヒト培養株化細胞
AU594014B2 (en) * 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
WO1986000639A1 (en) * 1984-07-06 1986-01-30 Sandoz Ag Lymphokine production and purification
JPS61227526A (ja) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
AU588819B2 (en) * 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
JPS62129298A (ja) * 1985-12-02 1987-06-11 Chugai Pharmaceut Co Ltd 新規ポリペプチド
WO1986004605A1 (en) * 1985-02-08 1986-08-14 Chugai Seiyaku Kabushiki Kaisha Human granulocyte colony stimulating factor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210007520A (ko) * 2019-07-12 2021-01-20 차원방 호안보강 및 확장을 위한 호안의 확장매립 시공방법

Also Published As

Publication number Publication date
ES8609365A1 (es) 1986-07-16
NL930141I2 (nl) 1997-03-03
AU585518B2 (en) 1989-06-22
HK50491A (en) 1991-07-12
DK337885A (da) 1986-01-26
CA1312569C (en) 1993-01-12
NO168952B (no) 1992-01-13
FI83881B (fi) 1991-05-31
DK166731B1 (da) 1993-07-05
FI852903L (fi) 1986-01-26
JPH0144200B2 (ko) 1989-09-26
DE3563444D1 (en) 1988-07-28
JPS61227526A (ja) 1986-10-09
KR920009496B1 (ko) 1992-10-17
BG61494B2 (bg) 1997-09-30
DK337885D0 (da) 1985-07-24
ES545502A0 (es) 1986-07-16
ATE35271T1 (de) 1988-07-15
US4833127A (en) 1989-05-23
NO852915L (no) 1986-01-27
AR242835A1 (es) 1993-05-31
EP0169566A1 (en) 1986-01-29
EP0169566B2 (en) 2000-07-12
ZA855478B (en) 1986-03-26
EP0169566B1 (en) 1988-06-22
FI852903A0 (fi) 1985-07-25
SG41591G (en) 1993-02-19
NO168952C (no) 1992-04-22
NL930141I1 (nl) 1994-01-03
FI83881C (fi) 1991-09-10
AU4513185A (en) 1986-01-30

Similar Documents

Publication Publication Date Title
KR860001185A (ko) Csf의 취득방법
Goodwin et al. The isolation and purification of the high mobility group (HMG) nonhistone chromosomal proteins
Bellamy et al. Evidence for procollagen, a biosynthetic precursor of collagen
Furuto et al. Isolation of a unique collagenous fraction from limited pepsin digests of human placental tissue. Characterization of one of the constituent polypeptide chains.
Dayton et al. A Ca2+ ion-activated protease possibly involved in myofibrillar protein turnover. Purification from porcine muscle
Goodwin et al. Isolation and characterisation of two calf‐thymus chromatin non‐histone proteins with high contents of acidic and basic amino acids
Wolfgram et al. THE COMPOSITION OF THE MYELIN PROTEINS OF THE CENTRAL NERVOUS SYSTEM 1 2
Vaughan et al. Proteoglycan Lt from chicken embryo sternum identified as type IX collagen.
NO860427L (no) Inhibin isolert fra ovarial follikkelv|ske.
PT100988A (pt) Processo para a purificacao de anticorpos
Rabbani et al. High mobility group non-histone chromosomal proteins from chicken erythrocytes
Carter Interferon: evidence for subunit structure
Mauritzen et al. The fractionation of arginine-rich histones from fetal calf thymus by exclusion chromatography
Lindahl et al. The linkage of heparin to protein
Veis et al. Evidence for an amino-terminal extension in high-molecular-weight collagens from mature bovine skin
Gillespie The Isolation and Properties of Some Soluble Proteins From Wool VII. The Heterogeneity of the High Sulphur Proteins
GB1534812A (en) Method for the purification of interferon
ES8200560A1 (es) Un procedimiento para producir interferon de fibroblasto hu-mano
Hnilica et al. Analysis of peptides of the moderately lysine rich histone fraction, F2b, of the walker tumor and other tissues
EP0206792A3 (en) High performance liquid chromatography mobile phase
Hogue‐Angeletti et al. Preparative separation and amino acid composition of neurofilament triplet proteins
Yamazaki et al. Purified rabbit interferon: attempts to demonstrate interferon-specific 3H-protein
PECKHAM et al. On the isolation of human pituitary follicle-stimulating hormone
Klyushnichenko et al. Recombinant human insulin: III. High-performance liquid chromatography and high-performance capillary electrophoresis control in the analysis of step-by-step production of recombinant human insulin
Brown et al. Heterogeneity of proteins resembling high-mobility-group protein HMG-T in trout testes nuclei.

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040730

Year of fee payment: 13

EXPY Expiration of term